Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
R2D2
Her2-positive Lung Cancer Treated With Dedicated Drug
- NCT03845270 ↗
- Completed
- Intergroupe Francophone de Cancerologie Thoracique
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on R2D2 (trastuzumab plus pertuzumab plus docetaxel in advanced non-small cell lung cancer harboring HER2 mutations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on R2D2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Stage III; HER2 Gene Mutation
- Interventions
- pertuzumab + trastuzumab + docetaxel
- Arms
- pertuzumab + trastuzumab + docetaxel · Experimental
- Enrollment
- 46
- Primary outcomes
- Overall Response
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Start
- May 17, 2019
- Primary completion
- Feb 1, 2021
- Results posted
- No
- Registry record
- NCT03845270 · updated Dec 19, 2023
Publications
linked from the registry- Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. J Clin Oncol. 2022 Mar 1;40(7):719-728. doi: 10.1200/JCO.21.01455. Epub 2022 Jan 24. PubMed 35073148